MicroRNA‑20b‑5p promotes ventricular remodeling by targeting the TGF‑β/Smad signaling pathway in a rat model of ischemia‑reperfusion injury

Liang,Zhao‑Guang; Yao,Hong; Xie,Rong‑Sheng; Gong,Chun‑Lin; Tian,Ye

doi:10.3892/ijmm.2018.3695

MicroRNA‑20b‑5p promotes ventricular remodeling by targeting the TGF‑β/Smad signaling pathway in a rat model of ischemia‑reperfusion injury

Authors:
- Zhao‑Guang Liang
- Hong Yao
- Rong‑Sheng Xie
- Chun‑Lin Gong
- Ye Tian
View Affiliations

Affiliations: Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
Published online on: May 18, 2018 https://doi.org/10.3892/ijmm.2018.3695
Pages: 975-987
Copyright: © Liang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Myocardial ischemic injury results from severe impairment of the coronary blood supply and may lead to metabolic and ultrastructural changes, thereby causing irreversible damage. MicroRNA (miR)‑20b‑5p has been demonstrated to be involved in malignancies of the breast, colorectum, stomach, blood and oropharynx. The present study aimed to investigate the effects of miR‑20b‑5p on ventricular remodeling following myocardial ischemia‑reperfusion (IR) injury in rats by targeting small mothers against decapentaplegic homolog 7 (Smad7) via the transforming growth factor‑β (TGF‑β)/Smad signaling pathway. A total of 70 adult male Sprague‑Dawley rats were divided into seven groups: Sham group, IR group, negative control group, miR‑20b‑5p mimics group, miR‑20b‑5p inhibitors group, small interfering RNA (siRNA)‑Smad7 group, and miR‑20b‑5p inhibitors + siRNA‑Smad7 group. Dual luciferase reporter gene assays were used to verify the association between miR‑20b‑5p and Smad7. Myocardial infarction size, myocardial collagen volume fraction and perivascular collagen area were detected separately using triphenyltetrazolium chloride and Masson's staining. The rate of positive expression of Smad7 was detected using immunohistochemistry, and the expression levels of miR‑20b‑5p, TGF‑β1, Smad3 and Smad7 were detected using reverse transcription‑quantitative polymerase chain reaction and western blot analyses. The findings revealed that miR‑20b‑5p inhibited Smad7. Compared with the sham group, the other six groups had increased myocardial infarction size, myocardial collagen, and expression of miR‑20b‑5p, TGF‑β1 and Smad3, and decreased expression of Smad7. Compared with the IR group, the miR‑20b‑5p mimics group and the siRNA‑Smad7 group had increased myocardial infarction size and myocardial collagen, increased expression of TGF‑β1 and Smad3, and decreased expression of Smad7. The expression of miR‑20b‑5p was markedly increased in the miR‑20b‑5p mimics group, but did not differ significantly from that in the siRNA‑Smad7 group. The results demonstrated that miR‑20b‑5p promoted ventricular remodeling following myocardial IR injury in rats by inhibiting the expression of Smad7 through activating the TGF‑β/Smad signaling pathway.

View Figures

View References

1	De Roeck L, Vandamme S, Everaert BR, Hoymans V, Haine S, Vandendriessche T, Bosmans J, Ronsyn MW, Miljoen H, Van Berendoncks A, et al: Adiponectin and ischemia-reperfusion injury in ST segment elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care. 5:71–76. 2016. View Article : Google Scholar
2	Selmer R, Halvorsen S, Myhre KI, Wisløff TF and Kristiansen IS: Cost-effectiveness of primary percutaneous coronary intervention versus thrombolytic therapy for acute myocardial infarction. Scand Cardiovasc J. 39:276–285. 2005. View Article : Google Scholar : PubMed/NCBI
3	Ong SB, Samangouei P, Kalkhoran SB and Hausenloy DJ: The mitochondrial permeability transition pore and its role in myocardial ischemia reperfusion injury. J Mol Cell Cardiol. 78:23–34. 2015. View Article : Google Scholar
4	Fröhlich GM, Meier P, White SK, Yellon DM and Hausenloy DJ: Myocardial reperfusion injury: Looking beyond primary PCI. Eur Heart J. 34:1714–1722. 2013. View Article : Google Scholar : PubMed/NCBI
5	Wick G, Grundtman C, Mayerl C, Wimpissinger TF, Feichtinger J, Zelger B, Sgonc R and Wolfram D: The immunology of fibrosis. Annu Rev Immunol. 31:107–135. 2013. View Article : Google Scholar : PubMed/NCBI
6	Neri M, Fineschi V, Di Paolo M, Pomara C, Riezzo I, Turillazzi E and Cerretani D: Cardiac oxidative stress and inflammatory cytokines response after myocardial infarction. Curr Vasc Pharmacol. 13:26–36. 2015. View Article : Google Scholar
7	Zhang M, Xu YJ, Saini HK, Turan B, Liu PP and Dhalla NS: TNF-alpha as a potential mediator of cardiac dysfunction due to intracellular Ca²⁺-overload. Biochem Biophys Res Commun. 327:57–63. 2005. View Article : Google Scholar : PubMed/NCBI
8	Hausenloy DJ and Yellon DM: The mitochondrial permeability transition pore: Its fundamental role in mediating cell death during ischaemia and reperfusion. J Mol Cell Cardiol. 35:339–341. 2003. View Article : Google Scholar : PubMed/NCBI
9	hao ZQ, Nakamura M, Wang NP, Velez DA, Hewan-Lowe KO, Guyton RA and Vinten-Johansen J: Dynamic progression of contractile and endothelial dysfunction and infarct extension in the late phase of reperfusion. J Surg Res. 94:133–144. 2000. View Article : Google Scholar
10	Hausenloy DJ and Yellon DM: Myocardial ischemia-reperfusion injury: A neglected therapeutic target. J Clin Invest. 123:92–100. 2013. View Article : Google Scholar : PubMed/NCBI
11	Fan ZX and Yang J: The role of microRNAs in regulating myocardial ischemia reperfusion injury. Saudi Med J. 36:787–793. 2015. View Article : Google Scholar : PubMed/NCBI
12	Suzuki HI and Miyazono K: Emerging complexity of microRNA generation cascades. J Biochem. 149:15–25. 2011. View Article : Google Scholar
13	Huntzinger E and Izaurralde E: Gene silencing by microRNAs: Contributions of translational repression and mRNA decay. Nat Rev Genet. 12:99–110. 2011. View Article : Google Scholar : PubMed/NCBI
14	He B, Xiao J, Ren AJ, Zhang YF, Zhang H, Chen M, Xie B, Gao XG and Wang YW: Role of miR-1 and miR-133a in myocardial ischemic postconditioning. J Biomed Sci. 18:222011. View Article : Google Scholar : PubMed/NCBI
15	Mukhopadhyay P, Das S, Ahsan MK, Otani H and Das DK: Modulation of microRNA 20b with resveratrol and longevinex is linked with their potent anti-angiogenic action in the ischaemic myocardium and synergestic effects of resveratrol and γ-tocotrienol. J Cell Mol Med. 16:2504–2517. 2012. View Article : Google Scholar
16	Dickinson BA, Semus HM, Montgomery RL, Stack C, Latimer PA, Lewton SM, Lynch JM, Hullinger TG, Seto AG and van Rooij E: Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure. Eur J Heart Fail. 15:650–659. 2013. View Article : Google Scholar : PubMed/NCBI
17	Li Y, Chen D, Jin L, Liu J, Su Z, Li Y, Gui Y and Lai Y: MicroRNA-20b-5p functions as a tumor suppressor in renal cell carcinoma by regulating cellular proliferation, migration and apoptosis. Mol Med Rep. 13:1895–1901. 2016. View Article : Google Scholar
18	Blahna MT and Hata A: Smad-mediated regulation of microRNA biosynthesis. FEBS Lett. 586:1906–1912. 2012. View Article : Google Scholar : PubMed/NCBI
19	Hanyu A, Ishidou Y, Ebisawa T, Shimanuki T, Imamura T and Miyazono K: The N domain of Smad7 is essential for specific inhibition of transforming growth factor-beta signaling. J Cell Biol. 155:1017–1027. 2001. View Article : Google Scholar : PubMed/NCBI
20	Zorzi F, Angelucci E, Sedda S, Pallone F and Monteleone G: Smad7 antisense oligonucleotide-based therapy for inflammatory bowel diseases. Dig Liver Dis. 45:552–555. 2013. View Article : Google Scholar : PubMed/NCBI
21	Cozzolino D, Sasso FC, Salvatore T, Torella M, Gentile S, Torella R and Giugliano D: Acute effects of beta-endorphin on cardiovascular function in patients with mild to moderate chronic heart failure. Am Heart J. 148:E132004. View Article : Google Scholar : PubMed/NCBI
22	Takagawa J, Zhang Y, Wong ML, Sievers RE, Kapasi NK, Wang Y, Yeghiazarians Y, Lee RJ, Grossman W and Springer ML: Myocardial infarct size measurement in the mouse chronic infarction model: Comparison of area- and length-based approaches. J Appl Physiol. 102:2104–2111. 2007. View Article : Google Scholar : PubMed/NCBI
23	Timmers L, Lim SK, Arslan F, Armstrong JS, Hoefer IE, Doevendans PA, Piek JJ, El Oakley RM, Choo A, Lee CN, et al: Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cell Res. 1:129–137. 2007. View Article : Google Scholar : PubMed/NCBI
24	Li XW, Wang XM, Li S and Yang JR: Effects of chrysin (5,7-dihydroxyf lavone) on vascular remodeling in hypoxia-induced pulmonary hypertension in rats. Chin Med. 10:42015. View Article : Google Scholar
25	Brown RS and Wahl RL: Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer. 72:2979–2985. 1993. View Article : Google Scholar : PubMed/NCBI
26	Li R, Yan G, Li Q, Sun H, Hu Y, Sun J and Xu B: MicroRNA-P145 protects cardiomyocytes against hydrogen peroxide (H₂O₂)-induced apoptosis through targeting the mitochondria apoptotic pathway. PLoS One. 7:e449072012. View Article : Google Scholar
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
28	Liu H, Shang J, Chu F, Li A, Wu B, Xie X, Liu W, Yang H and Tong T: Protective effects of Shen-Yuan-Dan, a traditional Chinese medicine, against myocardial ischemia/reperfusion injury in vivo and in vitro. Evid Based Complement Alternat Med. 2013:9563972013. View Article : Google Scholar
29	Cohn JN, Ferrari R and Sharpe N: Cardiac remodeling-concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. Behalf of an international forum on cardiac remodeling. J Am Coll Cardiol. 35:569–582. 2000. View Article : Google Scholar : PubMed/NCBI
30	Ito Y, Ito K, Shiroto T, Tsuburaya R, Yi GJ, Takeda M, Fukumoto Y, Yasuda S and Shimokawa H: Cardiac shock wave therapy ameliorates left ventricular remodeling after myocardial ischemia-reperfusion injury in pigs in vivo. Coron Artery Dis. 21:304–311. 2010. View Article : Google Scholar : PubMed/NCBI
31	Hagiwara S, Iwasaka H, Shingu C, Matumoto S, Hasegawa A and Noguchi T: Heat shock protein 47 (HSP47) antisense oligonucleotides reduce cardiac remodeling and improve cardiac function in a rat model of myocardial infarction. Thorac Cardiovasc Surg. 59:386–392. 2011. View Article : Google Scholar : PubMed/NCBI
32	Apstein CS: Increased glycolytic substrate protection improves ischemic cardiac dysfunction and reduces injury. Am Heart J. 139:S107–S114. 2000. View Article : Google Scholar : PubMed/NCBI
33	Galang N, Sasaki H and Maulik N: Apoptotic cell death during ischemia/reperfusion and its attenuation by antioxidant therapy. Toxicology. 148:111–118. 2000. View Article : Google Scholar : PubMed/NCBI
34	Fedak PW, Verma S, Weisel RD, Skrtic M and Li RK: Cardiac remodeling and failure: From molecules to man (Part III). Cardiovasc Pathol. 14:109–119. 2005. View Article : Google Scholar : PubMed/NCBI
35	Donekal S, Venkatesh BA, Liu YC, Liu CY, Yoneyama K, Wu CO, Nacif M, Gomes AS, Hundley WG, Bluemke DA and Lima JA: Interstitial fibrosis, left ventricular remodeling, and myocardial mechanical behavior in a population-based multiethnic cohort: The multi-ethnic study of Atherosclerosis (MESA) study. Circ Cardiovasc Imaging. 7:292–302. 2014. View Article : Google Scholar : PubMed/NCBI
36	Liu M, Chen J, Huang Y, Ke J, Li L, Huang D and Wu W: Triptolide alleviates isoprenaline-induced cardiac remodeling in rats via TGF-β1/Smad3 and p38 MAPK signaling pathway. Pharmazie. 70:244–250. 2015.PubMed/NCBI
37	Kasama S, Toyama T, Hatori T, Sumino H, Kumakura H, Takayama Y, Ichikawa S, Suzuki T and Kurabayashi M: Evaluation of cardiac sympathetic nerve activity and left ventricular remodelling in patients with dilated cardiomyopathy on the treatment containing carvedilol. Eur Heart J. 28:989–995. 2007. View Article : Google Scholar : PubMed/NCBI
38	Fazi F and Nervi C: MicroRNA: Basic mechanisms and transcriptional regulatory networks for cell fate determination. Cardiovasc Res. 79:553–561. 2008. View Article : Google Scholar : PubMed/NCBI
39	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
40	Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO, Landthaler M, et al: A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 129:1401–1414. 2007. View Article : Google Scholar : PubMed/NCBI
41	Zhao Y, Samal E and Srivastava D: Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature. 436:214–220. 2005. View Article : Google Scholar : PubMed/NCBI
42	Kretzschmar M and Massague J: SMADs: Mediators and regulators of TGF-beta signaling. Curr Opin Genet Dev. 8:103–111. 1998. View Article : Google Scholar : PubMed/NCBI
43	Chen Q, Chen H, Zheng D, Kuang C, Fang H, Zou B, Zhu W, Bu G, Jin T, Wang Z, et al: Smad7 is required for the development and function of the heart. J Biol Chem. 284:292–300. 2009. View Article : Google Scholar :
44	Wei LH, Huang XR, Zhang Y, Li YQ, Chen HY, Yan BP, Yu CM and Lan HY: Smad7 inhibits angiotensin II-induced hypertensive cardiac remodelling. Cardiovasc Res. 99:665–673. 2013. View Article : Google Scholar : PubMed/NCBI
45	Nagarajan RP, Zhang J, Li W and Chen Y: Regulation of Smad7 promoter by direct association with Smad3 and Smad4. J Biol Chem. 274:33412–33418. 1999. View Article : Google Scholar : PubMed/NCBI
46	Zhu X, Topouzis S, Liang LF and Stotish RL: Myostatin signaling through Smad2, Smad3 and Smad4 is regulated by the inhibitory Smad7 by a negative feedback mechanism. Cytokine. 26:262–272. 2004. View Article : Google Scholar : PubMed/NCBI